logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Acceleron Pharma Inc.


USPTO Granted Patents = 167



Forward Citations = 2,220

Loading Chart...
Loading Chart...

69 inventors (with patents filed for the assignee):

goldMedal Ravindra Kumar (114 out of 133 patents)

silverMedal Jasbir S Seehra (84 out of 109 patents)

bronzeMedal John L Knopf (75 out of 86 patents)

4.  Asya Grinberg (50 out of 65 patents)

5.  Dianne S Sako (36 out of 51 patents)

6.  Roselyne Castonguay (32 out of 33 patents)

7.  Robert Scott Pearsall (32 out of 32 patents)

8.  Matthew L Sherman (10 out of 13 patents)

9.  Jonathan Belk (8 out of 17 patents)

10.  Kenneth M Attie (8 out of 8 patents)

11.  Yossi Dagon (8 out of 9 patents)

12.  Rajasekhar Naga Venkata Sai Suragani (6 out of 6 patents)

13.  Naga Venkata Sai Rajasekhar Suragani (6 out of 6 patents)

14.  Nathan J Sharkey (5 out of 7 patents)

15.  Gang Li (5 out of 5 patents)


Core Competencies:
TGF-Beta Receptor Fusion Polypeptides
ALK7 Binding Proteins
Pulmonary Hypertension Treatments
Heterotopic Ossification
Muscular Dystrophy Therapies
Myelofibrosis Treatments
Anemia Treatment Methods
Fibrotic Disease Therapies
Red Blood Cell Production
ALK4:ActRIIB Heteromultimers
Activin Type 2 Receptor Antibodies
GDF15 Polypeptides

167 patents:

1. 12421295 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2025-09-23),
2. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),
3. 12364736 - Methods for treating heterotopic ossification (2025-07-22),
4. 12343378 - Compositions and methods for treating pulmonary hypertension (2025-07-01),
5. 12258380 - ALK4:actriib heteromultimers and uses thereof (2025-03-25),
6. 12240887 - Variant ActRIIB proteins and uses thereof (2025-03-04),
7. 12195519 - Transforming growth factor-beta (TGF-beta) receptor type II fusion polypeptides (2025-01-14),
8. 12194076 - Methods and compositions for treating myelofibrosis (2025-01-14),
9. 12168683 - Binders of TGFβ-superfamily ligands and uses thereof (2024-12-17),
10. 12145970 - Twisted gastrulation polypeptides and uses thereof (2024-11-19),
11. 12144860 - ALK1 receptor and ligand antagonists and uses thereof (2024-11-19),
12. 12103959 - Multispecific binders of TGFBeta-superfamily ligands and uses thereof (2024-10-01),
13. 12054753 - Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimers (2024-08-06),
14. 12042524 - Activin type 2 receptor binding proteins methods of making them (2024-07-23),
15. 12024563 - ALK7 antagonists and uses thereof (2024-07-02),
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for serious and rare diseases. They strive to transform the lives of patients by leveraging their deep understanding of biology, scientific innovation, and translational expertise. With a commitment to advancing novel therapies, Acceleron aims to improve outcomes and quality of life for patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
167 Patents

#16 in Cambridge, MA

#128 in Massachusetts

#2,302 in US

#4,802 in the World

...
Cambridge, MA, United States of America

Acceleron Pharma Inc.

Forward Citations = 2,220

69 inventors:

goldMedal Ravindra Kumar (114 out of 133 patents)

silverMedal Jasbir S Seehra (84 out of 109 patents)

bronzeMedal John L Knopf (75 out of 86 patents)

4.  Asya Grinberg (50 out of 65 patents)

5.  Dianne S Sako (36 out of 51 patents)

Please report any incorrect information to support@idiyas.com
Loading…